CLAAS Expands with New Ontario Dealership

Oct 30, 2025
By Farms.com

HJV Opens New Location in Winchester for Local Growers

CLAAS is expanding its reach across Canada with HJV’s new dealership in Winchester, Ontario. The regional dealer, already known for its strong service network, celebrated its grand opening on September 24, 2025, drawing more than 400 local farmers.

The new Winchester dealership offers the full CLAAS equipment lineup, including combines, tractors, and forage harvesters. This location strengthens CLAAS’ retail and service presence in one of Ontario’s most productive agricultural areas.

“CLAAS is a partner you can rely on,” said Jan-Hendrik Mohr, CEO of CLAAS Group. “We will continue to grow, investing across the entire value chain - from our expanded retail, service and supplier network to the North American R&D Center and the just-announced Customer Experience Center on our Omaha campus."

The Winchester site provides much-needed brick-and-mortar support, ensuring farmers benefit from in-person expertise and parts availability. This investment underscores CLAAS’ continued commitment to supporting Canadian growers through reliable equipment, local service, and innovation.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.